)
NEWS
Media Contacts:
Seqirus news releases
Seqirus news releases
The CSL Group collaborates with Global Plasma Leaders to accelerate development of potential COVID-19 Hyperimmune therapy
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19
Seqirus announces positive CHMP Opinion for its adjuvanted quadrivalent influenza vaccine
This news release is intended for medical and pharmaceutical trade media and financial media only
The CSL Group Offer To Help Battle Coronavirus
To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing.
New Data Demonstrate that FLUAD® (Influenza Vaccine, Adjuvanted) Significantly Reduces Hospitalization Risk for Adults 65+ Living in U.S. Nursing Homes Compared to Standard Trivalent Influenza Vaccine
Study highlights lower hospitalization rates in adults 65 years and older living in U.S. nursing homes who received an adjuvanted influenza vaccine versus standard trivalent influenza vaccine (TIV)
Seqirus Applauds the Executive Order to Accelerate Enhanced Protection Against Influenza Threats
The Executive Order represents a significant step towards accelerating access to more effective technologies, such as cell-based platforms, immunity-enhancing adjuvants, and other innovative approaches.
Seqirus opens new Centre of Excellence in Amsterdam
New laboratory and office space will enhance influenza vaccine research and development and help the company prepare for Brexit.
Seqirus and Laboratoire Arrow sign Distribution Agreement in France
This news release is intended for Health Professional media only.
Seqirus starts on time delivery of flu vaccines to support NHS immunisation programmes across the UK
This news release is intended for Health Professional media only.
Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses
Seqirus, a global leader in influenza prevention, today presented new scientific data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore that demonstrated circulating influenza B/Victoria (B/Vic) viruses are a closer match to cell-based B/Vic vaccine viruses compared with egg-based B/Vic vaccine viruses.
Seqirus to Present Data on Pandemic and Seasonal Influenza Vaccines at OPTIONS X Conference
Seqirus announced it will feature data in 3 presentations and 24 posters on the company’s adjuvant and cell-based vaccines for seasonal and pandemic influenza at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore.
Seqirus opens new Italian headquarters
Seqirus, a global leader in influenza prevention, today opened its new Italian headquarters in San Martino, Monteriggioni, just outside Siena.
Seqirus is First-to-Market with U.S. 2019/20 Influenza Vaccines
This news release is intended for business and trade media only.
First cell-based quadrivalent influenza vaccine approved for use in Europe
This news release is intended for Health Professional media only.
New Data on Cell-Based Seasonal Influenza Vaccines
This news release is intended for Health Professional media only.
Seqirus Announces U.S. $140 Million Manufacturing Expansion to Meet Growing Demand for Innovative Cell-Based Influenza Vaccines
The expansion will allow Seqirus to increase capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets.
Seqirus Cell-based Influenza Vaccine Nears European Approval
Subject to final approval by the European Commission, Seqirus plans to launch the vaccine as FLUCELVAX® TETRA1 in Europe for the 2019/20 influenza season.
Seqirus Joining UIVI to Advance Universal Flu Vaccine Research
Human Vaccines Project and Seqirus Partner to Advance Universal Flu Vaccine Research